Pelage Pharmaceuticals

Pelage Pharmaceuticals is a clinical-stage regenerative medicine company developing new therapies for hair loss, including androgenetic alopecia and chemotherapy-induced alopecia. Focused on molecular and stem cell biology, Pelage is advancing a novel treatment aimed at reactivating dormant hair follicle stem cells to restore the body's natural ability to grow hair. Its lead program, PP405, is currently in clinical trials. With its rigorous scientific foundation, topical formulation, and innovative mechanism of action, Pelage is pioneering a first-in-class hair growth solution suitable for all hair types experiencing hair loss.